Bottom line
XLV vs FHLC: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and FHLC (Fidelity MSCI Health Care Index ETF) have nearly the same top holdings — their top 25 positions are about 98% the same by weight.
But FHLC is far broader, holding 337 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
XLV is cheaper at 0.08% vs 0.084% — a difference of $0.40 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +7.2% for FHLC (reporting dates differ).
Updated Nov 19, 2026
XLV vs FHLC side by side
| XLV | FHLC | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | Fidelity |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.084% |
| Annual cost per $10k | $8 | $8.4 |
| 10-yr cost on $10k (prospectus) | $103 | $108 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +2.6% |
| 5-yr return (annualized) | +8.1% | +7.2% |
| 10-yr return (annualized) | +9.8% | +8.8% |
| Best quarter | +14.5% | +16.4% |
| Worst quarter | −12.7% | −13.1% |
| Net assets (fund) | $40.6B | $3.3B |
| Number of holdings | 65 | 337 |
| Portfolio turnover | 2% | 3% |
| Returns as of | Dec 31, 2025 | Nov 30, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | FHLC | Difference |
|---|---|---|---|
| 2024 | +2.5% | +2.6% | −0.1% |
| 2023 | +2.0% | +2.5% | −0.5% |
| 2022 | −2.1% | −5.5% | +3.4% |
| 2021 | +25.9% | +20.4% | +5.5% |
| 2020 | +13.3% | +18.1% | −4.9% |
| 2019 | +20.7% | +21.9% | −1.3% |
| 2018 | +6.3% | +5.5% | +0.8% |
| 2017 | +21.7% | +23.3% | −1.6% |
| 2016 | −2.8% | −3.3% | +0.5% |
Source: Fund prospectus bar charts
Holdings overlap
25 of XLV's top 25 holdings also appear in FHLC's top 25.
| Holding | XLV | FHLC |
|---|---|---|
| Eli Lilly & Co | 16.51% | 13.35% |
| Johnson & Johnson | 10.64% | 8.93% |
| AbbVie Inc | 7.74% | 6.42% |
| UnitedHealth Group Inc | 6.57% | 5.44% |
| Merck & Co Inc | 5.52% | 4.66% |
| Amgen Inc | 3.40% | 3.00% |
| Thermo Fisher Scientific Inc | 3.24% | 3.09% |
| Abbott Laboratories | 2.75% | 2.66% |
| Gilead Sciences Inc | 2.73% | 2.34% |
| Intuitive Surgical Inc | 2.45% | 1.82% |
| Pfizer Inc | 2.39% | 2.06% |
| CVS Health Corp | 2.30% | 1.92% |
| Vertex Pharmaceuticals Inc | 2.19% | 1.76% |
| Danaher Corp | 2.09% | 1.80% |
| Bristol-Myers Squibb Co | 2.05% | 1.93% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
FAQ
What is the difference between XLV and FHLC?
Which is cheaper, XLV or FHLC?
Should I own both XLV and FHLC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.